Asset Details
Do you wish to reserve the book?
Selective inhibition of long isoforms of phosphodiesterase 4D mitigates liver fibrosis in mouse models
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Selective inhibition of long isoforms of phosphodiesterase 4D mitigates liver fibrosis in mouse models
Do you wish to request the book?
Selective inhibition of long isoforms of phosphodiesterase 4D mitigates liver fibrosis in mouse models
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Selective inhibition of long isoforms of phosphodiesterase 4D mitigates liver fibrosis in mouse models
2026
Overview
Chronic inflammation leads to tissue fibrosis, which can disrupt the function of the parenchyma of the organ and ultimately lead to organ failure. The most prevalent form of this occurs in chronic hepatitis, which leads to liver fibrosis and, ultimately, cirrhosis and hepatic failure. Although there is no specific treatment for fibrosis, the phosphodiesterase 4 (PDE4) competitive inhibitors have been shown to ameliorate fibrosis in rodent models. However, competitive inhibitors of PDE4 have shown significantly reduced effectiveness due to severe gastrointestinal side effects. The PDE4 family is composed of 4 genes (PDE4A-D), with each having up to 9 differentially spliced isoforms. Here, we report that PDE4D expression is specifically elevated during the hepatic fibrosis stage of liver disease progression. Furthermore, the expression of the long isoforms of PDE4D is selectively elevated in activated hepatic stellate cells, leading to the enhanced accumulation of extracellular matrix components. In a mouse model of liver fibrosis, genetic ablation of PDE4D or pharmacological inhibition using D159687, a selective allosteric inhibitor targeting the long isoforms of PDE4D, suppresses the expression of inflammatory and profibrogenic genes. These findings establish the long isoforms of PDE4D as key drivers of liver fibrosis and highlight their potential as therapeutic targets to ameliorate liver fibrosis.
Subject
/ Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics
/ Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism
/ Hepatic Stellate Cells - enzymology
/ Hepatic Stellate Cells - pathology
/ Humans
/ Isoenzymes - antagonists & inhibitors
/ Liver Cirrhosis - drug therapy
/ Liver Cirrhosis - enzymology
/ Male
/ Mice
